Citric acid monohydrate pharma grade is used as the acid component in effervescent tablet and granule lines where controlled carbon dioxide generation is required for disintegration and palatability. The reaction with sodium bicarbonate proceeds on a stoichiometric basis of 1 mol citric acid monohydrate to 3 mol sodium bicarbonate, corresponding to a theoretical mass ratio of 210.14 g to 252.03 g, or 1.00 to 1.20. The chemically bound water in the monohydrate represents 8.57% w/w of the crystal and is not available to initiate acid-base reaction; the critical process variable is therefore free moisture introduced during granulation or compression. Effervescent blends are dried to a Karl Fischer water content below 0.3% w/w and compressed in a 20–25 °C environment at 30–40% relative humidity. Compression is performed on a rotary tablet press fitted with 32-station Euro B tooling and chromium-plated punches; precompression is set at 2–4 kN and main compression at 18–25 kN to avoid lamination of large-diameter effervescent tablets. Lubrication is typically achieved with 1–2% w/w sodium benzoate or polyethylene glycol 6000 rather than magnesium stearate because the latter can reduce tablet wettability. The finished tablets are packed in polypropylene tubes with 1 g silica gel desiccant or cold-form aluminum foil; the primary packaging moisture vapor transmission rate must be below 0.05 g/m²/day to prevent premature gas evolution. Disintegration acceptance is assessed according to USP <701>, with effervescent tablets expected to disintegrate within 5 minutes in water at 20–25 °C.

Which Tablet Core Defects Arise When Citric Acid Monohydrate Is Added Without Particle Size Control?

In direct-compression oral tablet cores, citric acid monohydrate is used at 2–10% w/w as an acidifying agent to create an acidic microenvironment around weakly basic APIs. The particle size of the acid controls the local pH gradient and the uniformity of acid dispersion. A specification of not less than 90% through a 250 µm sieve, verified by USP <786> analytical sieving or laser diffraction according to ISO 13320:2020, is applied before blending. Dissolution of weakly basic actives with pKa above 5 is evaluated in 900 mL of 0.1 M hydrochloric acid at 37 °C using USP <711> Apparatus 2 at 50 rpm; the acid component can shift the surface pH of the dissolving particle toward pH 3–4, increasing the local solubility of the API without altering the bulk dissolution medium. At compression suite humidity above 60% RH, citric acid monohydrate adsorbs surface water and becomes tacky, producing picking on the punch faces and capping at the edge of flat-faced, beveled-edge tooling. Production therefore holds the compression area at 20–25 °C and 30–40% RH and uses dust extraction at the press to remove fine acid particles. The acid must not be dry-blended with carbonate or bicarbonate fillers in non-effervescent cores because the resultant carbon dioxide pressure can cause leaks in the vacuum transfer system and segregation in the feed frame. Content uniformity is controlled by USP <905>, with acceptance values not exceeding 15 for a 10% w/w load.

Granule Densification and Binder-Free Agglomeration in Low-Shear Granulators

Citric acid monohydrate can act as a binder-free agglomeration agent during wet granulation because partial dissolution and recrystallization of the acid forms solid bridges between particles. In a planetary mixer with an impeller tip speed of 2–5 m/s, purified water or a 70:30 ethanol-water mixture is added at 8–12% w/w of the dry mass. When granulating fluid rises above 15% w/w, the acid dissolves extensively and produces oversized granules with a mean geometric diameter above 1.6 mm after drying; these granules show disintegration times exceeding 15 minutes in USP <701> testing. End-point control is monitored by measuring mixer power consumption, and granulation is stopped when the power signal rises by 15–25% above the dry mix baseline. Wet granules are discharged through a 1.0 mm screen and dried in a fluid-bed dryer with inlet air at 45–55 °C until residual moisture is below 4.0% w/w. The dried granules are sized through a 0.5 mm screen and filled into hard gelatin capsules using a tamping pin capsule filler with pin pressure between 60 N and 120 N. Granule flow is measured by the Hausner ratio; a value between 1.15 and 1.25 is considered adequate for tamping pin filling without excessive weight variation. Capsule fill weight uniformity is tested according to USP <905>; the acid-containing granule is also stored at 25 °C/60% RH in aluminum foil blister to prevent moisture-induced softening of the gelatin shell.

Injectable citrate buffer capacity is bounded by three pKa values and physiological osmolality constraints.

Parenteral formulations use citric acid monohydrate to generate citrate buffers without phosphate or acetate ions when the API is sensitive to phosphate-induced aggregation or when acetate is pharmacologically undesirable. At 25 °C, the triprotic acid has pKa1 3.13, pKa2 4.76, and pKa3 6.40; buffer capacity reaches local maxima near these values, but physiological compatibility and API stability confine most injectable formulations to pH 3.0–6.2. Small-volume parenterals are commonly formulated at 5–50 mM total citrate, whereas large-volume infusions are limited to lower concentrations because citrate ion chelates calcium and magnesium in plasma and can produce hypocalcemia in rapid infusion. Solutions are prepared in Water for Injection at 20–25 °C in 316L stainless steel tanks passivated according to ASTM A967; the surface roughness is controlled to Ra < 0.8 µm to prevent ion accumulation. The solution is filtered through a 0.22 µm sterilising-grade polyethersulfone filter and filled into Type I borosilicate glass vials conforming to USP <660>. Citric acid solutions can leach aluminum from Type III soda-lime glass surfaces; a formulation-specific elemental impurity risk assessment according to ICH Q3D and verification by USP <232>/<233> is therefore required for parenteral batches. The monohydrate used in injectable routes carries a low-endotoxin specification, typically below 0.5 EU/mg by USP <85>, and the final solution is tested for particulate matter by USP <788> and visible particles by USP <790>. Terminal sterilisation at 121 °C for 15 minutes can shift pH by 0.2–0.4 units through loss of dissolved carbon dioxide; nitrogen overlay during cooling is used to control the final pH. The resulting citrate-containing injection must not be mixed directly with calcium-containing infusions unless a physical compatibility study has demonstrated absence of calcium citrate precipitation.

Oral electrolyte granules and reconstitutable powders incorporate citric acid monohydrate when the formulation uses a bicarbonate source for effervescence and pH adjustment. Upon reconstitution in 200 mL potable water at 20–25 °C, the acid reacts with sodium bicarbonate to generate sodium citrate and carbon dioxide, shortening wetting time and masking the saline taste of sodium chloride. Replacement of trisodium citrate dihydrate with citric acid monohydrate plus sodium bicarbonate is calculated on a molar equivalence basis: 294.10 g of trisodium citrate dihydrate corresponds to 210.14 g citric acid monohydrate plus 252.03 g sodium bicarbonate. This substitution adds three moles of sodium per mole of citrate and increases bicarbonate-derived sodium; a sodium-equivalence review is therefore required before reformulating a WHO-reduced-osmolarity oral rehydration salt product. The reconstituted solution is tested for pH using USP <791> and for osmolality using freezing-point osmometry according to USP <785>. Typical target pH for reconstituted acid-based electrolyte granules is 4.0–5.5, and osmolality is adjusted by the sodium chloride and glucose content to remain below 300 mOsm/kg. Granules are filled into polyester/aluminum foil/low-density polyethylene sachets with moisture vapor transmission below 0.1 g/m²/day and stored at 25 °C/60% RH according to ICH Q1A. Published data for this specific configuration is limited, and formulation-specific stability must be generated before regulatory submission.

When Citric Acid Monohydrate Replaces Anhydrous Citric Acid in Anticoagulant Citrate Dextrose Solutions

Anticoagulant Citrate Dextrose Solution A (ACD-A) contains citric acid monohydrate at 8.0 g/L, trisodium citrate dihydrate at 22.0 g/L, and dextrose monohydrate at 24.5 g/L in Water for Injection. The pH of the terminally sterilized solution is controlled to 5.0–5.5, measured at 20–25 °C by USP <791>. When a master formula specifies anhydrous citric acid, the monohydrate quantity is calculated by multiplying the anhydrous mass by 1.094; omission of the correction yields 8.6% less anhydrous citric acid equivalent and shifts the final pH upward because less acidic species is present. The solution is compounded in 316L stainless steel, filtered through a 0.22 µm membrane, filled into flexible polyvinyl chloride containers, and steam-sterilized at 121 °C for 15 minutes. Post-sterilisation checks include pH, extractable volume, and particulate matter according to USP <788>. The citric acid monohydrate used in this application must meet bacterial endotoxin limits by USP <85> and elemental impurities by USP <232>/<233>. The citrate ion reduces ionized calcium in whole blood by forming soluble chelates; the anticoagulant effect is dependent on citrate concentration and blood contact time. ACD-A must not be mixed with calcium-containing intravenous solutions in the same line because calcium citrate precipitation can obstruct the infusion path.